○Terufumi Kato1, Hirotsugu Kenmotsu2, Kazushige Wakuda2, Keita Mori3, Shunichi Sugawara4, Keisuke Kirita5, Isamu Okamoto6, Koichi Azuma7, Kazumi Nishino8, Shunsuke Teraoka9, Ryo Koyama10, Ken Masuda11, Hidetoshi Hayashi12, Ryo Toyozawa13, Satoru Miura14, Yuki Sato15, Kazuhiko Nakagawa12, Nobuyuki Yamamoto9, Toshiaki Takahashi2 (1.Department of Thoracic Oncology, Kanagawa Cancer Center, 2.Division of Thoracic Oncology, Shizuoka Cancer Center, 3.Clinical Research Support Center, Shizuoka Cancer Center, 4.Department of Pulmonary Medicine, Sendai Kousei Hospital, 5.Department of Thoracic Oncology, National Cancer Center Hospital East, 6.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 7.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 8.Department of Thoracic Oncology, Osaka International Cancer Institute, 9.Internal Medicine III, Wakayama Medical University, 10.Department of Respiratory Medicine, Juntendo University, 11.Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, 12.Department of Medical Oncology, Faculty of Medicine, Kindai University, 13.Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 14.Department of Internal Medicine, Niigata Cancer Center Hospital, 15.Department of Respiratory Medicine, Kobe City Medical Center General Hospital)
Session information
Oral Session
[O6] Oral Session 6 Lung Cancer / Thoracic Cancer 1(Molecularly-targeted therapy EGFR, ALK)
【E】
Thu. Feb 17, 2022 1:10 PM - 2:40 PM Room 11 and 12 (Prince Hall 1 and 2, B2F, The Prince Kyoto Takaragaike)
Chair:Koichi Goto(Department of Thoracic Oncology, National Cancer Center Hospital East),Takashi Seto(Department Thoracic Oncology, NHO Kyushu Cancer Centre)
Discussant:Hidetoshi Hayashi(Department of Medical Oncology, Kindai University)
○Isamu Okamoto1, Helena Yu2, Helen Ambrose3, Christina Baik4, Byoung Chul Cho5, Emiliano Cocco6, Sarah B Goldberg7, Jonathan Goldman8, Silvija Kraljevic3, Adrianus Johannes De Langen9, Zofia Piotrowska10, Michael Pluta11, Julie Maidment12, Noemí Reguart13, Jonathan W Riess14, Xiuning Le15 (1.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 2.Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, 3.Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK, 4.Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, USA, 5.Division of Medical Oncology, Yonsei Cancer Center, Seoul, Republic of Korea, 6.Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA, 7.Yale School of Medicine, New Haven, CT, USA, 8.UCLA, Los Angeles, CA, USA, 9.Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, 10.Department of Medicine, Massachusetts General Hospital, Boston, MA, USA, 11.Early Oncology, Oncology Statistics, AstraZeneca, Cambridge, UK, 12.Patient Safety Oncology, Chief Medical Office, AstraZeneca, Cambridge, UK, 13.Department of Medical Oncology, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic de Barcelona, Barcelona, Spain, 14.Internal Medicine – Haematology/Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA, 15.Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA)
○Takeshi Masuda1, Satoru Miura2, Hidenori Koso3, Kazuhiro Yanagihara4, Tatsuro Okamoto5, Hiroyasu Shoda6, Junichi Shimizu7, Nobuhiro Kanaji8, Satoshi Hara9, Shinya Sakata10, Takaaki Tokito11, Kosuke Kashiwabara12, Kazuo Nishikawa13, Hiroshi Watanabe14, Ken Maeno15, Shigeki Suzuki16, Daisuke Hayakawa17, Nobuyuki Yamamoto18, Kazuhiko Nakagawa19, Hattori Noboru1 (1.Department of Respiratory Medicine, Hiroshima University Hospital, 2.Department of Internal Medicine, Niigata Cancer Center Hospital, 3.Department of Surgery, National Hospital Organization, Oita Medical Center, 4.Department of Medical Oncology, Kansai Electric Power Hospital, 5.Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 6.Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, 7.Department of Thoracic Oncology, Aichi Cancer Center Hospital, 8.Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, 9.Department of Respiratory Medicine, Itami City Hospital, 10.Department of Respiratory Medicine, Kumamoto University Hospital, 11.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 12.Department of Respiratory Medicine, Kumamoto Regional Medical Center, 13.Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, 14.Department of Respiratory Medicine, Saka General Hospital, 15.Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 16.Department of General Thoracic Surgery, Sagamihara Kyodo Hospital, 17.Department of Respiratory Medicine, Juntendo University Faculty of Medicine, 18.Department of Internal Medicine III, Wakayama Medical University, 19.Department of Medical Oncology, Kindai University Faculty of Medicine)
○Atsushi Nakamura1, Hidetoshi Hayashi2, Takehiro Uemura3, Shigeki Mitsuoka4, Kentaro Ito5, Junji Uchida 6, Yosuke Tamura7, Yasuo Iwamoto8, Masahide Oki9, Satoru Kitazono10, Yoshikazu Hasegawa11, Akihito Kubo12, Katsuhiko Naoki13, Satoshi Ikeda15, Kageaki Watanabe16, Yasutaka Chiba17, Kazuko Sakai18, Kazuto Nishio18, Nobuyuki Yamamoto18, Kazuhiko Nakagawa Kazuhiko Nakagawa2 (1.Department of Pulmonary Medicine, Sendai Kousei Hospital, 2.Department of Medical Oncology, Kindai University Faculty of Medicine, 3.Nagoya City University Hospital, 4.Department of Clinical Oncology, Graduate School of Medicine, Osaka City University, 5.Respiratory Center, Matsusaka Municipal Hospital, 6.Department of Respiratory Medicine, Osaka General Medical Center, 7.Osaka Medical and Pharmaceutical University, 8.Hiroshima City Hiroshima Citizens Hospital, 9.Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, 10.Cancer Institute Hospital, Japanese Foundation for Cancer Research , 11.Izumi City General Hospital, 12.Aichi Medical University School of Medicine, 13.Department of Respiratory Medicine, Kitasato University School of Medicine, 14.Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 15.Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 16.Clinical Research Center, Kindai University Hospital, 17.Department of Genome Biology, Kindai University Faculty of Medicine, 18.Internal Medicine III, Wakayama Medical University)
○Hye Ryun Kim1, Sanjay Popat2, Myung-Ju Ahn3, James Ch Yang4, Ji-Youn Han5, Maximilian J Hochmair6, Ki Hyeong Lee7, Angelo Delmonte8, Maria Rosario Garcia Campelo9, Dong-Wan Kim10, Frank Griesinger11, Enriqueta Felip12, Raffaele Califano13, Alexander I Spira14, Scott N Gettinger15, Marcello Tiseo16, Huamao M Lin17, Yuyin Liu17, Florin Vranceanu17, D Ross Camidge18 (1.Yonsei Cancer Center, Yonsei University College of Medicine, 2.Royal Marsden Hospital, London, England, United Kingdom, 3.Samsung Medical Center, Seoul, South Korea, 4.National Taiwan University Cancer Center, Taipei, Taiwan, 5.National Cancer Center, Goyang, South Korea, 6.Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna, Austri, 7.Chungbuk National University Hospital, Cheongju, South Korea, 8.Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola, Italy, 9.University Hospital A Coruña, CHUAC, A Coruña, Spain, 10.Seoul National University Hospital, Seoul, South Korea, 11.Pius-Hospital Oldenburg, University of Oldenburg, Germany, 12.Vall d'Hebron University Hospital, Barcelona, Spain, 13.The Christie NHS Foundation Trust, Manchester, England, United Kingdom, 14.Virginia Cancer Specialists and US Oncology Research, The Woodlands, TX, USA, 15.Yale Cancer Center, New Haven, CT, USA, 16.University Hospital of Parma, Parma, Italy, 17.Takeda Development Center Americas, Inc., Lexington, MA, USA, 18.University of Colorado Cancer Center, Aurora, CO, USA)
○Naoki Haratake1, Khin Kyaemon Thwin2, Mei Matsumoto2, Yasutaka Watanabe3, Hirotsugu Kenmotsu4, Shoichi Itoh5, Ken Uchibori6, Ayako Shiono7, Aoi Hino8, Toshihide Yokoyama9, Yukihiro Toi10, Hisashi Tanaka11, Hidetoshi Hayashi12, Eisaku Miyauchi13, Naoki Ishizuka14, Yusuke Kajihara15, Yuki Nakagawa16, Kazuma Kiyotani17, Siew-Kee Low17, Ryohei Katayama2 (1.Department of Surgery and Science, Kyushu University Hospital, 2.Div of Experimental Chemotherapy, The Cancer Chemotherapy Center of JFCR, 3.Division of Thoracic Oncology, Saitama Cancer Center, 4.Division of Thoracic Oncology, Shizuoka Cancer Center, 5.Department of Thoracic Oncology, Hyogo Cancer Center, 6.Department of Thoracic Medical Oncology, The Cancer Institute Hospital of JFCR, 7.Department of Respiratory Medicine, Saitama Medical University International Medical Center, 8.Department of Respiratory Medicine, Chiba University Hospital, 9.Department of Respiratory Medicine, Kurashiki Central Hospital, 10.Department of Respiratory Medicine, Sendai Kousei Hospital, 11.Department of Respiratory Medicine, Hirosaki University Hospital, 12.Department of Medical Oncology, Kindai University Hospital, 13.Department of Respiratory Medicine, Tohoku University Hospital, 14.Department of Clinical Trial planning and Management, The Cancer Institute Hospital of JFCR, 15.Medical Science Dept., Chugai Pharmaceutical Co., Ltd., 16.Biometrics Dept., Chugai Pharmaceutical Co., Ltd., 17.The Cancer Precision Medicine Center of JFCR)